Allergy & Immunology
Opinion | “Oxford-AstraZeneca Vaccine Safety: Reports of blood clots after receiving the AstraZeneca COVID-19 vaccine are very likely just background events.”
18 Mar, 2021 | 09:09h | UTCRelated: Update on the safety of COVID-19 Vaccine AstraZeneca (statement and commentaries) AND What is Going on With the AstraZeneca/Oxford Vaccine? – Science Translational Medicine
COVID-19 vaccines vs. variants—determining how much immunity is enough
18 Mar, 2021 | 08:58h | UTCCOVID-19 Vaccines vs Variants—Determining How Much Immunity Is Enough – JAMA
Population Study: Past Covid-19 confers 80.5% protection against reinfection, which decreases to 47.1% in those aged 65 years and older
18 Mar, 2021 | 09:06h | UTCCommentaries: Risk of SARS-CoV-2 reinfection after natural infection – The Lancet AND COVID-19 Reinfection: More Common Than We Think? – MedPage Today (free registration required)
Commentary on Twitter
NEW—Most people who have had original #COVID19 strain are protected from catching it again for at least 6 months—but those ≥65 years are more prone to reinfection, suggests first large-scale study of its kind. Read https://t.co/250Yv0a9BZ pic.twitter.com/BTjhcMzXwT
— The Lancet (@TheLancet) March 17, 2021
[Preprint] Delaying second vaccine dose leaves cancer patients vulnerable to virus
17 Mar, 2021 | 02:58h | UTCNews release: Delaying second vaccine dose leaves cancer patients vulnerable to virus – King’s College London
Commentaries: Expert reaction to preprint looking at antibody immune response following one dose of Pfizer COVID-19 vaccine in cancer patients – Science Media Centre AND Cancer patients ‘lack same protection’ after first jab – BBC
Immunogenicity of a single dose of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients
17 Mar, 2021 | 02:55h | UTC
Antibody response after SARS-CoV-2 infection and implications for immunity: A rapid living review
16 Mar, 2021 | 02:30h | UTC
ACP Practice Points: What is the antibody response and role in conferring natural immunity after SARS-CoV-2 infection?
16 Mar, 2021 | 02:29h | UTC
The first 12 months of COVID-19: a timeline of immunological insights
16 Mar, 2021 | 02:22h | UTCThe first 12 months of COVID-19: a timeline of immunological insights – Nature Reviews Immunology
Commentary on Twitter
We've learned a lot on the immune response and multiple discoveries throughout the covid-19 pandemic and I can't imagine it could be better summarized than by this new @NatRevImmunol paper or these authors @CyrilPedia @florian_krammer @VirusesImmunity https://t.co/6SOSP5URFf pic.twitter.com/nOCTOzmzBY
— Eric Topol (@EricTopol) March 15, 2021
Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
14 Mar, 2021 | 20:43h | UTCEpidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes – Science
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
14 Mar, 2021 | 20:44h | UTCMultiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity – Cell
Commentary: Vaccine-induced antibodies may be less effective against several new SARS-CoV-2 variants
Commentary on Twitter (thread – click for more)
Our paper describing the potential for mRNA vaccines to induce antibodies capable of neutralizing many of the circulating variants is now available online at Cell!https://t.co/c8B87Tg55S pic.twitter.com/eRM8ABJrQY
— Balazs Lab (@BalazsLab) March 12, 2021
Perspective | Long Covid isn’t as unique as we thought
12 Mar, 2021 | 08:27h | UTCLong Covid isn’t as unique as we thought – Vox
Perspective | Immunity to SARS-CoV-2 variants of concern
12 Mar, 2021 | 08:24h | UTCImmunity to SARS-CoV-2 variants of concern – Science
Commentary on Twitter
https://twitter.com/EricTopol/status/1370094431668375552
[Press release – not published yet] Monoclonal antibodies reduced hospitalizations and death in Phase 3 trial for early COVID-19
11 Mar, 2021 | 08:41h | UTCPress release: Lilly’s bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19
Commentary: Eli Lilly’s combo therapy for COVID-19 cuts serious illness and death in large study – Reuters
[Preprint] RECOVERY trial: Convalescent plasma does not improve outcomes in patients admitted to hospital with COVID-19
11 Mar, 2021 | 08:43h | UTC
Commentary on Twitter (thread – click for more)
RECOVERY Pre-print:
Convalescent plasma does not improve survival in patients hospitalised with COVID-19 in this randomised controlled trial involving 11,558 patients:https://t.co/36YZwJNY3Q pic.twitter.com/sKR095n1PC
— Martin Landray (@MartinLandray) March 10, 2021
More data suggesting a single dose of SARS-CoV-2 mRNA vaccine may be enough in seropositive individuals
11 Mar, 2021 | 08:18h | UTCRelated: Studies: Single dose of vaccine acts as ‘booster’ in those with prior COVID-19 infection (studies and commentary) AND Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2 – JAMA
Review: Autoimmune enteropathy and its associated syndromes
10 Mar, 2021 | 08:10h | UTCA Review of Autoimmune Enteropathy and Its Associated Syndromes – Digestive Diseases and Sciences
M-A: Serological evidence of human infection with SARS-CoV-2
10 Mar, 2021 | 08:42h | UTCInvited Commentary: COVID-19 serosurveys for public health decision making – The Lancet Global Health
Commentary on Twitter (thread – click for more)
Now out: our systematic review and meta-analysis on seroprevalence surveys for SARS-CoV-2 is now out @LancetGH, collaboration with Hongjie Yu and team @FudanUniv. #COVID19. A short thread: 1/n https://t.co/EHLTc9AUCq
— Daniel T Leung (@GlobalGutHealth) March 9, 2021
Lab study shows Pfizer/BioNTech COVID-19 vaccine can also neutralize B.1.351, P1 and B.1.1.7 variants
10 Mar, 2021 | 08:43h | UTCNeutralizing Activity of BNT162b2-Elicited Serum – New England Journal of Medicine
Commentaries: Expert reaction to NEJM correspondence paper looking at the neutralising activity of the Pfizer-BioNTech vaccine against SARS-CoV-2 variants in the lab – Science Media Centre AND Pfizer/BioNTech COVID-19 vaccine neutralizes Brazil variant in lab study – Reuters
New study of Coronavirus variants predicts virus evolving to escape current vaccines, treatments
9 Mar, 2021 | 02:49h | UTCOriginal study: Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 – Nature
Commentary on Twitter
The B.1.351 and B.1.1.7 SARS-CoV-2 variants (first detected in South Africa and the UK, respectively) show increased resistance to antibody neutralization in laboratory experiments, according to a study in Nature. https://t.co/k0QBoeim6F pic.twitter.com/czyNYMBGxF
— Nature Portfolio (@NaturePortfolio) March 8, 2021
[Preprint] Systematic review: Characteristics of SARS-CoV-2 reinfection vs. persistent COVID-19
9 Mar, 2021 | 02:44h | UTCSARS-CoV-2 Sequence Characteristics of COVID-19 Persistence and Reinfection – medRxiv
Commentary: How can physicians distinguish between COVID-19 persistence and SARS-CoV-2 reinfection? – News Medical
Cardiovascular disease risk in immune-mediated inflammatory diseases: recommendations for clinical practice
7 Mar, 2021 | 19:20h | UTC
WHO: The effects of virus variants on COVID-19 vaccines
7 Mar, 2021 | 20:09h | UTCThe effects of virus variants on COVID-19 vaccines – World Health Organization
Some experience delayed rash after Moderna shot, study says
5 Mar, 2021 | 08:44h | UTCSome Experience Delayed Rash After Moderna Shot, Study Says – Bloomberg
Original study: Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2 – New England Journal of Medicine
A Review of Persistent Post-COVID Syndrome (PPCS)
4 Mar, 2021 | 08:45h | UTCA Review of Persistent Post-COVID Syndrome (PPCS) – Clinical Reviews in Allergy & Immunology
NIH halts trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms
3 Mar, 2021 | 08:55h | UTC